1315 Capital acquired Biocoat.

1315 Capital, a Philadelphia-based healthcare investment firm that provides expansion and growth capital to commercial-stage healthcare services, medical technology, and specialty pharmaceutical companies acquired Biocoat a 27-year old privately held company. Financial terms were not disclosed. The acquisition of Biocoat by 1315 Capital will assist the Company in taking a more aggressive and growth-oriented approach in the biomaterial coatings market for medical devices, a market projected to reach over $15bn by 2021. “Biocoat’s combination of differentiated technology within an expanding market and growth-focused management team makes it a great fit for 1315 Capital and we’re excited to be working with Jim and his team,” Michael Koby, 1315 Capital Co-Founding Partner. The transaction originally closed on December 20, 2018.